PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
CCR5 and HIV Infection
January 2015
HIV/AIDS: Pre-fusion Env Exposed
January 2015
HIV/AIDS: Slide to Enter
January 2015
Updating ModBase
January 2015
Power in Numbers
August 2014
Quorum Sensing: A Groovy New Component
August 2014
Bacterial CDI Toxins
June 2014
Immunity: One Antibody to Rule Them All
June 2014
Virology: A Bat Influenza Hemagglutinin
March 2014
Virology: Making Sensitive Magic
March 2014
Virology: Visualizing Cyanophage Assembly
March 2014
Virology: Zeroing in on HBV Egress
March 2014
Viroporins
March 2014
Cas4 Nuclease and Bacterial Immunity
February 2014
Microbial Pathogenesis: A GNAT from Pseudomonas
February 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Microbiome: The Dynamics of Infection
September 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Infectious Diseases: A Pathogen Ubiquitin Ligase
May 2013
Infectious Diseases: A Shared Syringe
May 2013
Infectious Diseases: Determining the Essential Structome
May 2013
Infectious Diseases: Targeting Meningitis
May 2013
NDM-1 and Antibiotics
May 2013
Bacterial Hemophores
January 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Microbial Pathogenesis: NEAT Iron
January 2013
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
A signal sensing switch
September 2012
Gauging needle structure
July 2012
Anthrax Stealth Siderophores
June 2012
A Pseudomonas L-serine dehydrogenase
May 2012
Pilus Assembly Protein TadZ
April 2012
Making Lipopolysaccharide
January 2012
Superbugs and Antibiotic Resistance
December 2011
A change to resistance
November 2011
An effective and cooperative dimer
November 2011
The Perils of Protein Secretion
November 2011
Bacterial Armor
October 2011
Breaking down the defenses
September 2011
Moving some metal
August 2011
Capsid assembly in motion
April 2011
Know thy enemy … structurally
October 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Hemolysin BL
January 2010
Unusual cell division
October 2009
Anthrax evasion tactics
September 2009
Toxin-antitoxin VapBC-5
September 2009
Antibiotic target
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
You look familiar: the Type VI secretion system
June 2009
Unique SARS
April 2009
Anthrax stealth molecule
March 2009
A new class of bacterial E3 ubiquitination enzymes
January 2009
Antiviral evasion
October 2008
SARS connections
September 2008
SARS Coronavirus Nonstructural Protein 1
June 2008

Research Themes Infectious diseases

A change to resistance

SBKB [doi:10.1038/sbkb.2011.47]
Featured Article - November 2011
Short description: Two structures of NDM-1 β-lactamase show how this enzyme can confer resistance to many antibiotics.

The active site of NDM-1, in which many of the residues responsible for substrate binding and catalysis are on flexible loops. Image courtesy of Jim Sacchettini.

The most widely used family of antibiotics, the β-lactams, have been a mainstay of clinical therapy since the discovery of penicillin in the early twentieth century. However, pathogenic bacteria have countered the widespread use of β-lactams through the continual adaptation of β-lactamase enzymes that catalyze their hydrolysis. In particular, the recently discovered New Delhi metallo-β-lactamase (NDM-1) enzyme has raised public health concern, as it confers resistance to all known β-lactam antibiotics, including the carbapenem class of β-lactams, which are generally considered the last line of defense. As part of the PSI MTBI partnership, Sacchetini (University of Texas Medical Branch), Joachimiak (PSI MCSG) and colleagues report two crystal structures of NDM-1 that explain this enzyme's broad substrate activity and may help in the future design of NDM-1 inhibitors.

The structures of NDM-1 show that its ability to hydrolyze many β-lactam substrates is due to its large and flexible active site. Compared to other metallo-β-lactamases, the active site of NDM-1 is 2 to 13 times larger in volume. This expanded size stems in part from the conformation of two active site loops, ASL1 and ASL4. In other metallo-β-lactamases these loops bridge over the active sites, whereas in NDM-1 they seem to be splayed outward, leading to a more open conformation of the active site and allowing greater access to potential substrates. Furthermore, amino acid substitutions in these loops, particularly in ASL1, allow them greater flexibility in correctly positioning a broad range of β-lactams for hydrolysis.

By capturing NDM-1 in both the apo and singly zinc-bound forms, the researchers have also shed insight into the catalytic mechanism of β-lactam inactivation. The structures suggest that NDM-1 can exist in three states, defined by whether the enzyme is bound to zero, one or two metals, and that hydrolysis of the β-lactam ring is facilitated by the activation of a zinc-bound water molecule. This mechanism is similar to that described for other metallo-β-lactamases, and may provide a basis for targeting other enzymes of the same family.

In conclusion, the structures of NDM-1 may contribute to the rational design of new drugs capable of treating bacteria that have acquired broad-spectrum antibiotic resistance.

Timothy Silverstein

References

  1. Y. Kim et al. Structure of apo- and monometalated forms of NDM-1—a highly potent carbapenem-hydrolyzing metallo-β-lactamase.
    PLoS ONE 6, e24621 (2011). doi:10.1371/journal.pone.0024621

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health